Table 1.
Demographic and baseline characteristics, safety population
| Characteristics | Inotuzumab ozogamicin treatment | ||
|---|---|---|---|
| 1.3 mg/m2 (n = 3) | 1.8 mg/m2 (n = 10) | Total (n = 13) | |
| Median age, years (range) | 57 (51–66) | 48 (43–72) | 49 (43–72) |
| Sex, n (%) | |||
| Female | 2 (67) | 4 (40) | 6 (46) |
| Male | 1 (33) | 6 (60) | 7 (54) |
| ECOG performance status, n (%) | |||
| 0 | 3 (100) | 10 (100) | 13 (100) |
| Primary diagnosis, n (%) | |||
| Follicular lymphoma | 3 (100) | 10 (100) | 13 (100) |
| FLIPI risk groups, n (%) | |||
| Low | 2 (67) | 3 (30) | 5 (39) |
| Intermediate | 1 (33) | 5 (50) | 6 (46) |
| High | 0 | 2 (20) | 2 (15) |
| Number of prior chemo‐/immunotherapy regimens, n (%) | |||
| 1 | 2 (67) | 6 (60) | 8 (62) |
| 2 | 0 | 0 | 0 |
| 3 | 0 | 1 (10) | 1 (8) |
| ≥4 | 1 (33) | 3 (30) | 4 (31) |
ECOG, Eastern Cooperative Oncology Group; FLIPI, Follicular Lymphoma International Prognostic Index.